IBRX Live signaler | Maksimer profitt med Getagraph.com

KJøP 106026 min ago

@ $4.52

Utstedt: 14 feb 2024 @ 19:58

Avkastning: 62.79%

Forrige signal: feb 14 - 15:30

Forrige signal: Selg

Avkastning: 4.24 %

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 22:00):

Stats
Dagens volum	39.08M
Gjennomsnittsvolum	5.40M
Markedsverdi	4.95B
EPS	$-0.350 ( 2024-03-20 )
Neste inntjeningsdato	( $-0.160 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.39
ATR14	$0.117 (1.59%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-22	Simon Barry J.	Buy	159 146	Stock Option (right to buy)
2024-02-22	Simon Barry J.	Buy	45 731	Restricted Stock Units
2024-02-22	Lauer Regan J	Buy	42 439	Stock Option (right to buy)
2024-02-22	Lauer Regan J	Buy	12 195	Restricted Stock Units
2024-02-22	Sachs David C.	Buy	424 390	Stock Option (right to buy)

INSIDER POWER
99.24
Last 97 transactions
Buy: 228 380 025 \| Sell: 921 083

Volum Korrelasjon

Lang: 0.53 (weak)

Kort: -0.15 (neutral)

Signal:(48.073) Neutral

ImmunityBio, Inc. Korrelasjon

10 Mest positive korrelasjoner
SIRI	0.928
RGF	0.928
FGBI	0.925
AROW	0.921
ALRS	0.92
GNTY	0.92
CBNK	0.915
GSMG	0.914
GOOD	0.906
ALLK	0.906

10 Mest negative korrelasjoner
RIVE	-0.933
DSEY	-0.93
DUOL	-0.927
AMPH	-0.926
RAM	-0.919
INTA	-0.919
PLYA	-0.918
ALTR	-0.91
DAIO	-0.909
MLTX	-0.907

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

ImmunityBio, Inc. Korrelasjon - Valuta/Råvare

0.51
( weak )

0.64
( weak )

0.00
( neutral )

0.23
( neutral )

0.04
( neutral )

0.83
( strong )

ImmunityBio, Inc. Økonomi

Annual	2023
Omsetning:	$622 000
Bruttogevinst:	$-17.89M (-2 876.21 %)
EPS:	$-1.150

FY	2023
Omsetning:	$622 000
Bruttogevinst:	$-17.89M (-2 876.21 %)
EPS:	$-1.150

FY	2022
Omsetning:	$240 000
Bruttogevinst:	$-23.95M (-9 980.00 %)
EPS:	$-1.040

FY	2021
Omsetning:	$934 000
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-0.893

Financial Reports:

No articles found.

ImmunityBio, Inc.

ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.